Phase II study of @entity1206 with low dose XXXX in the treatment of hormone-refractory metastatic @entity263 .

@entity1 @entity137 @entity263 @entity417 @entity229 @entity1206 @entity1431 @entity158
A phase II trial of @entity1206 and low dose @entity229 in hormone-refractory metastatic @entity263 was conducted in order to investigate its safety, efficacy and impact on quality of life. @entity1206 was administered at the dose of 25 mg/m(2) i.v. weekly for 12 weeks and then biweekly, along with 10 mg of daily oral @entity229 until time of progression. Fourteen @entity1 , median age of 74 years, were treated. The treatment was generally well tolerated with @entity1431 and @entity417 as the major side effects. One @entity1 achieved partial remission and eleven remained with stable disease. One of the eleven @entity1 with stable disease had a dramatic PSA response from 1000 to 236 ng/ml; seven of these progressed after week twelve when @entity1206 was given biweekly. PSA response occurred in 5 of 14 @entity1 . The median time to progression was 28 weeks and the median survival was 17 months. Nine out of the 14 accrued @entity1 were evaluable for quality of life assessment. Five of them improved, three remained unchanged and two had a slight worsening. Four @entity1 had improvement in @entity158 control and fatigue. Our preliminary data suggest that the combination of @entity1206 / @entity229 has modest activity in metastatic @entity263 with a very favorable @entity137 profile and is very well tolerated in this group of elderly @entity1 .
